Blood Vessel Repair Cells and Heart Complications in Type 2 Diabetes
Studies blood vessel repair cells in adults with type 2 diabetes and heart problems.
Plain-language title generated from the registry record
Registry title: Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes
Key facts
- Where
- Doha, QatarSee the site
Where in Qatar
- Hamad Medical CorporationDoha, QatarTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Weill Cornell Medical College in Qatar
- Trial code
- NCT07556497
- Record updated
- 29 April 2026
- Original description
This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.Read full original descriptionShow less
Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes
This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.
Inclusion: T2D; Males and females; Older than 18 years of age; Willingness to participate in the study and provide written consent form; Consent to having peripheral blood withdrawals and urine collection for the study requirement.
Exclusion: Type I diabetes, MODY diabetes or other form of diabetes; Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to); Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis); Evidence of malignancy within the past 5 years; Unable to meet the inclusion criteria.